VERA — Vera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1831828 ·
Last close
$42.00
Market Cap
$3.01B
52W High
$45.73
52W Low
$30.59
ADV30
2,090,268
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -125,132,000 | -121,032,000 | 621,739,000 | 114,351,000 | 122,042,000 |
| Dec 2025 | 0 | — | -94,206,000 | -91,097,000 | 734,733,000 | 354,725,000 | 130,212,000 |
| Sep 2025 | 0 | — | -83,932,000 | -80,293,000 | 517,503,000 | 57,773,000 | 118,623,000 |
| Jun 2025 | 0 | — | -80,141,000 | -76,531,000 | 578,528,000 | 49,121,000 | 110,251,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-241,104,000
Investing CF
$194,286,000
Financing CF
$308,897,000
CapEx
$-630,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-760,865,000
Inventory
—
Receivables
$3,285,000
ST Investments
$359,864,000
EBIT TTM
$-292,084,000
Pretax Income TTM
$-299,614,000
Interest Exp TTM
$7,530,000
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -315,473,000 | -299,615,000 | 734,733,000 | 130,212,000 | — | -241,104,000 |
| Dec 2024 | 0 | -167,170,000 | -152,148,000 | 655,681,000 | 78,526,000 | — | -134,679,000 |
| Dec 2023 | 0 | -102,012,000 | -95,990,000 | 175,546,000 | 73,861,000 | — | -92,181,000 |
| Dec 2022 | 0 | -90,903,000 | -89,056,000 | 131,435,000 | 54,527,000 | — | -67,596,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.84
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | $2.94B | $63.44 | — |
| QURE | uniQure N.V. | $2.93B | $42.63 | — |
| IRON | Disc Medicine, Inc. | $2.93B | $76.59 | — |
| MBX | MBX Biosciences, Inc. | $2.91B | $61.05 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.81B | $48.46 | — |
News headlines (Yahoo Finance, 1h cache)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?
2026-07-10 17:12 · Yahoo
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval
2026-07-10 14:14 · Yahoo
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run
2026-07-10 11:14 · Yahoo
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
2026-07-09 12:00 · Yahoo
Sector Update: Healthcare Stocks Gain Late Afternoon
2026-07-07 19:51 · Yahoo
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
2026-07-07 18:33 · Yahoo
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
2026-07-07 16:37 · Yahoo
Vera Therapeutics wins FDA nod for closely watched kidney disease drug
2026-07-07 07:47 · Yahoo
Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)
2026-07-06 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.